The expression of CBL-B in human atherosclerotic plaques was lower in advanced lesions compared with initial lesions and correlated inversely with necrotic core area. Twenty weeks old Cblb À/À Apoe À/À mice showed a significant increase in plaque area in the aortic arch, where initial plaques were present. In the aortic root, a site containing advanced plaques, lesion area rose by 40%, accompanied by a dramatic change in plaque phenotype. Plaques contained fewer macrophages due to increased apoptosis, larger necrotic cores, and more CD8 þ T cells.
Cblb À/À Apoe À/À macrophages exhibited enhanced migration and increased cytokine production and lipid uptake.
Casitas B-cell lymphoma-B deficiency increased CD8 þ T cell numbers, which were protected against apoptosis and regulatory T cell-mediated suppression. IFNc and granzyme B production was enhanced in Cblb 
Introduction
Atherosclerosis, a lipid-driven inflammatory disease of the large arteries, is the underlying cause of the majority of cardiovascular diseases (CVD). 1 Although primary and secondary preventive strategies have significantly lowered the incidence of CVD, atherosclerosis remains a major cause of morbidity and mortality. 2 Additional therapeutic strategies, which target the residual cardiovascular risk that persists after optimal pharmacological treatment, are therefore required. 2 In addition to dyslipidaemia, immune cell activation and subsequent inflammation drive atherogenesis. [1] [2] [3] Inhibition of atherosclerosis-associated inflammation is therefore a strategy with a great therapeutic potential, as highlighted by the CANTOS (Canakinumab Antiinflammatory Thrombosis Outcome Study) trial, in which antibody-mediated inhibition of interleukin (IL)-1b reduced the incidence of recurrent CVD in patients with a previous myocardial infarction and high residual inflammatory risk. 4 T cells constitute a variable but substantial proportion of the immune cell population in the atherosclerotic plaque and are significant drivers of the inflammatory responses that underlie atherosclerosis. . 1 The function of CD8 þ cytotoxic T cells in atherosclerosis is incompletely understood; however, they appear proatherogenic and are abundantly present in advanced human atherosclerotic lesions. 3 Transfer of CD8 þ T cells accelerates atherosclerosis and leads to a vulnerable plaque phenotype in Apoe À/À mice, whereas antibody-mediated depletion of CD8 þ T cells impedes the formation of atherosclerotic lesions. 3, 5, 6 Despite the well-described functions of T cell subsets in atherosclerosis, the regulatory mechanisms by which they undergo activation and polarization during atherogenesis are less extensively studied.
The Casitas B-cell lymphoma (CBL) E3 ubiquitin ligasescomprising CBL-B, C-CBL, and CBL-C-form one of the protein families that modulate T cell activation and polarization. 7 Casitas B-cell lymphoma-B promotes T cell tolerance through ubiquitination and degradation of downstream effectors, such as phosphoinositide phospholipase Cc and phosphoinositide 3-kinase, and thus is a negative regulator of T cell activation. 7, 8 Casitas B-cell lymphoma-B-deficient T cells have a hyper responsive phenotype that is accompanied by CD28-independent activation, due to their lower threshold for T cell receptor-mediated responses. 9 Further, these T cells mount delayed responses to anergic signals, contributing to a state of hyper responsiveness. 10 Notably, macrophages, an important cell type that abounds in atherosclerotic plaques, also expresses CBL-B, the function of which in this cell type remains incompletely described.
7 Casitas B-cell lymphoma-B deficiency is linked to enhanced toll-like receptor (TLR)4 signalling and increased macrophage activation and migration in dietinduced obesity 11 and lung inflammation models, 12 processes that are also relevant for the atherosclerosis. Considering the significant regulatory activity of CBL-B in T cell and macrophage biology, we evaluated the expression pattern of CBL-B in human atherosclerotic lesions and investigated the function of CBL-B in experimental atherosclerosis.
Methods

Human studies
Coronary artery specimens were obtained from autopsy from the Department of Pathology of the Amsterdam UMC and immediately fixed in 10% formalin and processed for paraffin embedding. All use of tissue was in agreement with the 'Code for Proper Secondary Use of Human Tissue in the Netherlands'. CBL-B expression was analysed by immunohistochemistry, as described in the Supplementary material online. Gene expression of CBL-B in human atherosclerosis was examined by microarray-based transcriptional profiling of carotid endarterectomy specimens (BiKE dataset 13, 14 ).
Animal studies
Male Cblb À/À Apoe À/À and Apoe À/À mice were bred and housed at the animal facility of the University of Amsterdam and kept on a normal chow diet. All mice were treated according to the study protocol (permit nos. 102601 and 102869) that were approved by the Committee for Animal Welfare of the University of Amsterdam, the Netherlands. Detailed methods are provided in the Supplementary material online.
Translational perspective
In this study, we demonstrate that the E3-ligase Casitas B-cell lymphoma-B (CBL-B) is expressed in human atherosclerotic plaques, and that its expression decreases with plaque progression. Using an atherosclerotic mouse model, we found that CBL-B exerts profound anti-atherogenic effects by regulating CD8 þ T cell and macrophage activation. Activation of CBL-B, therefore, represents a promising anti-inflammatory therapeutic strategy in atherosclerosis. Figure 1A-C) . A negative correlation between plaque area and CBL-B expression ( Figure 1D) , and necrotic core area and CBL-B was observed ( Figure 1E ), indicating that CBL-B expression in the plaque decreased during the progression of atherosclerosis. The majority of CBL-B þ cells were CD68 þ macrophages ( Figure 1F ) and CD3 þ T cells ( Figure 1G ), whereas only few intraplaque vascular smooth muscle cells (VSMCs) and endothelial cells expressed CBL-B (data not shown).
To further evaluate the expression of CBL-B in human atherosclerosis, gene expression of CBL-B in carotid endarterectomy specimens was examined by microarray-based transcriptional profiling (BiKE dataset 13, 14 ) Carotid atherosclerotic lesions had a tendency to express less CBL-B mRNA when compared with non-atherosclerotic arteries (P = 0.056) ( Figure 1H ). Casitas B-cell lymphoma-B was not differentially expressed between atherosclerotic plaques from symptomatic and asymptomatic patients (data not shown), indicating that CBL-B predominantly affects plaque development and not plaque rupture.
Casitas B-cell lymphoma-B deficiency aggravates atherosclerosis in Apoe À/À mice Casitas B-cell lymphoma-B is expressed in CD68 þ macrophages and CD3 þ T cells in murine atherosclerotic plaques (Supplementary material online, Figure S1 ). To study the function of CBL-B in atherosclerosis, Cblb À/À Apoe À/À and Apoe À/À mice were generated and fed a normal chow diet for 20 weeks. The extent and phenotype of atherosclerosis was determined in the aortic arch and the aortic root ( Figure 2A) . Body weight or basic haematologic parameters did not differ between genotypes (Supplementary material online, Table S1 ).
Histological analysis of over 20 organs revealed no abnormalities, particularly no signs of autoimmunity, in Cblb
Deficiency of CBL-B increased atherosclerotic plaque area in the aortic arch and its main branch points by 1.8-fold ( Figure 2B and C). Most plaques in the aortic arch were early, macrophage rich lesions ( Figure 2C ). Immunohistochemistry demonstrated that the plaques of Cblb À/À Apoe À/À mice contained significantly more CD45 þ cells ( Figure 2D ), reflecting a more inflammatory plaque phenotype. Plaques in the aortic roots of Cblb À/À Apoe À/À and Apoe À/À mice were not only larger ( Figure 2E ), but also displayed hallmarks of advanced stages of atherosclerosis, especially necrotic core formation ( Figure 2F ). Deficiency of CBL-B resulted in a 1.4-fold increase in atherosclerotic plaque area. Plaques in the aortic root of Cblb À/À Apoe À/À mice contained fewer CD68 þ macrophages when compared with Apoe À/À mice ( Figure 2G and H), which resulted from increased macrophage apoptosis ( Figure 2I ) and a subsequent increase in necrotic core area ( Figure 2J and K). 
Casitas B-cell lymphoma-B deficiency induces an atherogenic phenotype in macrophages
Considering the profound increase in early, macrophage-rich lesions observed in the aortic arch and incremented necrotic core formation in the more advanced stages of atherosclerosis in Cblb À/À Apoe À/À mice, we analysed the effects of CBL-B on monocytes and macrophages. Deficiency of CBL-B increased the expression of the chemokine receptors CCR1, CCR2, and CCR5, all of which mediate leucocyte recruitment into the arterial wall, in primary monocytes and bone marrow-derived macrophages (BMDMs) ( Figure 3A and B). Transcript levels of CCR7, a chemokine receptor that governs macrophage egress in atherosclerosis, 15 also increased ( Figure 3A and B).
Consistent with these findings, Cblb À/À Apoe À/À monocytes and
BMDMs exhibited an increased migratory capacity towards CCL2 ( Figure 3C and D).
Lipopolysaccharide stimulated Cblb À/À Apoe À/À BMDMs produced significantly more reactive oxygen species (ROS) ( Figure 3E and F), TNF ( Figure 3G and H), and IL6 ( Figure 3I ), whereas IL10 expression was reduced ( Figure 3J ). Moreover, CBL-B-deficient BMDMs expressed significantly more MHC-II, pointing towards increased antigen presenting capacity of these cells ( Figure 3K) . Expression of the M1 macrophage marker iNOS was increased in aortic arch lysates of Cblb À/À Apoe À/À mice, the M2 markers arginase 1 and CD206 were not affected (Supplementary material online, Figure S2A ). Upon phagocytosis and cytoplasmic storage of lipoproteins, macrophages evolve into foam cells, the predominant constituent of atherosclerotic plaques. Notably, CBL-B transcript levels decreased during foam cell formation (Supplementary material online, Figure  S2B ). Casitas B-cell lymphoma-B-deficient BMDMs expressed higher protein levels of the scavenger receptor CD36 ( Figure 3L ) and ingested significantly more oxLDL ( Figure 3M ), whereas the cholesterol efflux genes ABCA1 and ABCG1 were not affected (Supplementary material online, Figure S2C ). Thus, deficiency of CBL-B enhanced the migratory potential of macrophages, promoted the expression of inflammatory mediators and increased lipid uptake, resulting in an atherogenic macrophage phenotype.
Casitas B-cell lymphoma-B deficiency increases the abundance of CD8 þ T cells by reducing apoptosis and regulatory T-cells-mediated suppression 12.0 ± 3.2% Cblb À/À Apoe À/À ; P ¼ 0.08), specifically due to a significant increase in cytotoxic CD8 þ T cells (2.05 ± 1.41% Apoe À/À vs.
5.00 ± 2.05% Cblb À/À Apoe À/À ; P ¼ 0.003) ( Figure 4A and B). These findings were supported by flow cytometry, verifying skewing towards more CD8 þ T cells in the aortic arch, blood and spleen ( Figure 4C ). In the absence of CBL-B, CD8 þ T cells shifted from naïve
no differences in the effector memory T cell compartment (CD62L -CD44 þ ) ( Figure 4D ), suggesting enhancement of their activation status.
Next, we studied the potential mechanism underlying the increased abundance of CD8 þ T cells and found that CBL-B deficiency enhanced the production of IL2 ( Figure 4E and F), a potent growth factor for T cells. 
Casitas B-cell lymphoma-B deficiency increases the cytotoxicity of CD8 þ T cells and provokes macrophage death
To further characterize, the effects of CBL-B deficiency on cytotoxic T cell function, splenic CD8 þ T cells were isolated and the production of effector proteins was analysed.
showed a significant increase in IFNc protein levels compared with Apoe À/À CD8 þ T cells ( Figure 5A and B) . Moreover, CBL-B-deficient cytotoxic T cells expressed higher levels of granzyme B ( Figure 5C and D), a protein described to promote atherosclerosis by inducing apoptosis in plaque-associated cells. -pulsed BMDMs ( Figure 5E and F) . These data indicate that the enhanced cytotoxicity of CD8 þ T cells, in conjunction with their increased abundance ( Figure 4A-C) , provoked macrophage killing and necrotic core formation in the plaques of Cblb À/À Apoe À/À mice.
CD8
þ T cell are the main drivers of atherogenesis in Cblb
To further evaluate the contribution of Cblb
was transplanted into lethally irradiated Apoe À/À recipient mice.
Following 6 weeks of recovery, antibody-mediated depletion of CD8 þ T cells was initiated and continued for 6 weeks until the assessment of atherosclerosis in the aortic arch and aortic root ( Figure 6A ). Anti-CD8 treatment successfully depleted circulating CD8 þ T cells in both Cblb À/À Apoe À/À and Apoe À/À recipients ( Figure 6B ). CD8 þ T cells were also successfully depleted in the lymphoid organs and only a minor increase in CD4 þ T cells was observed in Cblb À/À Apoe À/À chimeras (Supplementary material online, Figure S3 ). Haematopoietic CBL-B deficiency did not affect plaque area in the aortic arch, which contained only very initial plaques (Supplementary material online, Figure S4 ), but markedly increased plaque In the aortic root, where more advanced plaques were present, haematopoietic deficiency of CBL-B resulted in a 1.8-fold increase in lesion area ( Figure 7A and B) . Depletion of Cblb À/À Apoe À/À CD8 þ T cells prevented this increase ( Figure 7A and B) and ameliorated plaque inflammation, as reflected by the decrease in CD45 þ cells ( Figure 7C ).
Although MAC3
þ content was not affected by haematopoietic CBL-B deficiency ( Figure 7D) , depletion of CD8 þ T cells prevented the increase in necrotic core formation that was observed in Cblb À/À Apoe À/À bone marrow chimeras ( Figure 7E and F) . This experiment, which demonstrates that depletion of CD8 þ T cells improves plaque inflammation and halts the progression of atherosclerosis in CBL-B-deficient bone marrow chimeras, indicates that the atheroprotective effect of CBL-B predominantly relies on its function in cytotoxic T cells.
Discussion
Here, we report that CBL-B, the 'natural inhibitor' of T cell activation, has a critical function in atherosclerosis. The expression of CBL-B in human atherosclerotic plaques is lower in advanced lesions when compared with initial lesions and negatively correlated with necrotic core area, indicating that CBL-B expression decreases during the progression of atherosclerosis. Absence of CBL-B aggravates initial atherosclerosis in Apoe monocytes and hampering macrophage accumulation and apoptosis in the plaque. 6 Accordingly, adoptive transfer of CD8 þ T-cells aggravated atherosclerosis and increased necrotic core formation in Apoe À/À Rag À/À mice, due to granzyme B-and perforin-induced macrophage death, resulting in clinically unfavourable high-risk plaques. 5 In the current study, we confirmed that an excess of CD8 þ T cells is detrimental in atherosclerosis, particularly due to the increase in CD8 þ T cell-mediated macrophage apoptosis and necrotic core formation.
One cause of the increase in CD8 þ T cells in Cblb À/À Apoe À/À mice is the lower susceptibility to Treg-mediated suppression. A similar phenotype has been found in Cblb À/À CD4 þ T cells, which had developed resistance to TGFb due to SMAD7-mediated down-regulation of TGFbR-II. 16 In our study, CBL-B-deficient CD8 þ T cells also expressed less TGFbR-II, rendering them less prone to TGFb-mediated Treg suppression. Furthermore, Tregs suppress T cell proliferation by capturing IL2, thereby limiting IL2-dependent T-cell proliferation. 17 We found that Cblb
cells, lowering their sensitivity to
Treg-mediated reductions in IL2.
In addition, we demonstrate that CBL-B promotes the suppressive effects of Tregs, which contrasts previous findings that showed no effect of CBL-B ablation on Tregmediated suppression in in vitro polyclonal CD8 þ T-cell proliferation assays. 18 This discrepancy might be due to the use of stimulating anti-CD28 and anti-CD3 beads in our study vs. irradiated splenocytes and CD3 stimulation in the earlier reports. 18 In such an experimental setup, Tregs can modulate antigen-presenting cells, interfering with T cell activation, in addition to the suppressive effects on CD8 þ T cells.
In addition to the significant effect on CD8 þ T cells, CBL-B deficiency also resulted in an atherogenic phenotype in monocytes and macrophages, characterized by an increased migratory potential, increased cytokine production and lipid uptake. Little is known about the function of CBL-B in cells of myeloid origin, but it has been demonstrated that CBL-B mediates TLR4 ubiquitination and impedes the association of the adhesion proteins Lymphocyte Functionassociated Antigen 1 (LFA-1) and Intercellular Adhesion Molecule 1 (ICAM-1), thereby inhibiting adhesion and diapedesis. 19 In other disease models, such as diet-induced obesity and sepsis, CBL-B deficiency enhanced the infiltration of macrophages into adipose tissue, causing insulin resistance in obesity, and excessive macrophage infiltration into the lung during sepsis. 11, 12 Our study shows that CBL-B deficiency not only increased the migratory potential of monocytes and macrophages, but also increased the production of inflammatory mediators, which accelerates plaque initiation. Accordingly, we found that depletion of CD8 þ T cells in haematopoietic Cblb À/À Apoe À/À mice did not affect lesion formation in the very early stage of atherosclerosis, which is primarily monocyte/macrophage-driven. In the later stages of atherosclerosis, depletion of CD8 þ T cells reduced plaque area, plaque inflammation and necrotic core formation, indicating that the progression of atherosclerosis in CBL-B-deficient mice was predominantly driven by CD8 þ T cells.
Conclusion
In summary, this study demonstrates that CBL-B puts a brake on CD8 þ T cell activation during atherogenesis, thereby inhibiting plaque inflammation and progression towards a clinically unfavourable high-risk plaque phenotype. Although our experimental results should be extrapolated to patients with caution and the effects of targeting ubiquitination in specific immune cells must be scrutinized before being translated into a clinical application, our study attributes a critical role to CBL-B in the regulation of cytotoxic T cell-driven responses in atherosclerosis and provides the basis for novel CBL-Btargeting therapeutic strategies.
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